Skip to content

Histocell. Regenerative Medicine vs StemSight - Vision Unlimited

Histocell. Regenerative Medicine logo

Histocell. Regenerative Medicine

Advanced therapy medicinal products, medical devices and dermocosmetics for regenerative medicine

41 employees · est. 2004 · Derio, Spain

VS
StemSight - Vision Unlimited logo

StemSight - Vision Unlimited

Curing blindness with regenerative cell therapies

16 employees · est. 2021 · Tampere, Finland

Histocell. Regenerative Medicine is the older company (2004 vs 2021).

Side-by-Side Comparison

Histocell. Regenerative Medicine StemSight - Vision Unlimited
Founded
2004 older 2021
Headquarters
Derio, Spain Tampere, Finland
Employees
41 16
Industry
Biotechnology, Health Care, Medical Devices Biotechnology, Health Care, Health and Wellness
Funding Stage
Grant Seed
Total Funding
$7.00M $2.80M
Funding Rounds
4 2
Taxonomy
BiopharmaceuticalRegenerative MedicineCell TherapyDermocosmeticsGMP CertificationStem Cells +8 Regenerative MedicineCell TherapyCorneal BlindnessStem CellsIPS-Derived CellsBiomaterials +3
Website
histocell.com stemsight.fi
Histocell. Regenerative Medicine logo

About Histocell. Regenerative Medicine

Histocell. Regenerative Medicine Histocell is a clinical-stage biopharmaceutical company dedicated to developing advanced therapy medicinal products, medical devices, and dermocosmetics for regenerative medicine, with a primary focus on controlling oxidative stress to improve people's quality of li...

StemSight - Vision Unlimited logo

About StemSight - Vision Unlimited

StemSight is a biotechnology startup based in Finland, founded in 2021. The company's slogan, "Curing blindness with regenerative cell therapies," encapsulates its mission to develop off-the-shelf regenerative cell therapies for corneal blindness. StemSight's innovative approach involves the combina...

Also comparing in this category

Comparing more than these two?

Get Histocell. Regenerative Medicine, StemSight - Vision Unlimited and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Histocell. Regenerative Medicine compare?

A PDF of Histocell. Regenerative Medicine and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Histocell. Regenerative Medicine was founded in 2004, based in Derio, Spain, with 41 employees. Histocell. Regenerative Medicine Histocell is a clinical-stage biopharmaceutical company dedicated to developing advanced therapy medicinal products, medical devices, and dermocosmetics for regenerati. StemSight - Vision Unlimited was founded in 2021, based in Tampere, Finland, with 16 employees. StemSight is a biotechnology startup based in Finland, founded in 2021. The company's slogan, "Curing blindness with regenerative cell therapies," encapsulates its mission to develop off-the-shelf reg.
Histocell. Regenerative Medicine has raised $7.00M and StemSight - Vision Unlimited $2.80M. Latest stage: Histocell. Regenerative Medicine Grant, StemSight - Vision Unlimited Seed.
Both work in Biotechnology and Health Care and list regenerative medicine, cell therapy and stem cells among their focus areas.

Compare Histocell. Regenerative Medicine with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Histocell. Regenerative Medicine on 11 Sep 2024, and StemSight - Vision Unlimited on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout